To participate, please dial one of the following numbers and ask to join the Verona Pharma call: A live webcast will be available on the Events and Presentations link on the Investors page of the ...

Canaccord raised the firm’s price target on Verona Pharma (VRNA) to $72 from $44 and keeps a Buy rating on the shares. The firm believes the ...

Shares of Verona Pharma plc (NASDAQ:VRNA – Get Free Report) reached a new 52-week high on Wednesday after Canaccord Genuity Group raised their price target on the stock from $44.00 to $72.00.

Shares of Verona Pharma stock opened at $60.26 on Wednesday. The company has a quick ratio of 12.88, a current ratio of 13.03 and a debt-to-equity ratio of 0.93. Verona Pharma has a twelve month ...

Verona Pharma PLC (NASDAQ:VRNA) shares have reached an all-time high, touching a price level of $62.09. According to ...

Verona Pharma (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed ...

To participate, please dial one of the following numbers and ask to join the Verona Pharma call: Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 ...

Summary The Chart of the Day belongs to biotechnology company Verona Pharma (VRNA) . I found the stock by using Barchart's ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Verona Pharma. Looking at options history for Verona Pharma VRNA we detected 14 trades. If we consider the specifics ...

On Tuesday, H.C. Wainwright analyst increased the price target on shares of Verona Pharma (NASDAQ:VRNA) to $60 from the previous target of $42, maintaining a Buy rating on the shares. The ...